Lin Zhao | Neuropathic Pain | Best Researcher Award

Prof. Dr. Lin Zhao | Neuropathic Pain | Best Researcher Award

China Medical university | China

AUTHOR PROFILE

Scopus

👨‍🎓 EARLY ACADEMIC PURSUITS

Prof. Dr. Lin Zhao began his academic journey with a strong foundation in medical sciences and neuroscience. He pursued his undergraduate and graduate studies at prestigious institutions, focusing on the mechanisms of neuropathic pain. His passion for understanding pain pathways led him to China Medical University, where he honed his expertise in neurobiology, pain modulation, and therapeutic interventions.

🏥 PROFESSIONAL ENDEAVORS

Dr. Zhao holds a key academic and research position at China Medical University. Over the years, he has been involved in:

  • Leading groundbreaking research in the field of neuropathic pain.
  • Mentoring Ph.D. and postgraduate students specializing in pain research.
  • Collaborating with international institutions to develop novel pain therapies.
  • Serving on editorial boards and scientific committees, contributing to the peer-review process of major pain-related journals.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS

Dr. Zhao’s research focuses on neuropathic pain mechanisms, pain signaling pathways, and novel treatment strategies. His key contributions include:

  • Uncovering the molecular and cellular basis of chronic pain conditions.
  • Exploring innovative drug targets for pain management.
  • Developing non-invasive pain therapies such as neurostimulation and pharmacological interventions.
  • Publishing high-impact research papers in international medical journals.

🌍 IMPACT AND INFLUENCE

Dr. Zhao’s research has had a profound impact on the medical field, particularly in:

  • Advancing clinical treatments for neuropathic pain.
  • Enhancing the understanding of chronic pain disorders and their underlying causes.
  • Shaping medical guidelines and therapeutic approaches in pain management.
  • Influencing pain research globally through his findings and collaborations.

📚 ACADEMIC CITATIONS AND RECOGNITION

Prof. Zhao has received numerous citations for his work in neuropathic pain, reflecting his scientific influence. His H-index and impact factor stand as a testament to his significant contributions. He has also:

  • Published extensively in SCI-indexed journals.
  • Received prestigious research grants and awards.
  • Been recognized as a leading figure in the field of pain research.

🚀 LEGACY AND FUTURE CONTRIBUTIONS

Looking ahead, Dr. Zhao’s legacy in neuropathic pain research continues to grow. His future contributions may include:

  • Pioneering new pain relief therapies using cutting-edge technologies.
  • Expanding his mentorship programs to nurture the next generation of pain researchers.
  • Enhancing interdisciplinary collaborations to integrate neuroscience, pharmacology, and biomedical engineering for better treatment solutions.
  • Driving policy changes in pain management and healthcare systems.

🎯 FINAL THOUGHTS

Prof. Dr. Lin Zhao stands as a pillar in neuropathic pain research, with his work paving the way for more effective, patient-centered treatments. His dedication to science, innovation, and education ensures that his contributions will continue to shape the field for years to come.

🏆 CONCLUSION

Prof. Dr. Lin Zhao has revolutionized the field of neuropathic pain research, making significant scientific and clinical advancements that have shaped modern pain management strategies. His dedication to understanding pain mechanisms, developing novel therapies, and mentoring future researchers has established him as a leading expert in the field.

 

📊🔬NOTABLE PUBLICATION:
  1. Title: Improved efficacy of cisplatin delivery by peanut agglutinin‑modified liposomes in non‑small cell lung cancer
    Authors: B., Yang, Ben , R., Kou, Rongguan , H., Wang, Hui , … W., Yu, Wenjing , Z., Gao, Zhiqin
    Journal: International Journal of Molecular Medicine
    Year: 2024

 

  1. Title: Novel analgesic peptide derived from Cinobufacini injection suppressing inflammation and pain via ERK1/2/COX-2 pathway
    Authors: L., Guo, Li , S., Zhang, Sai , C., Zhang, Cong , … Y., Gao, Yuanyuan , T., Sun, Tongyi
    Journal: International Immunopharmacology
    Year: 2024

Kalim Ullah | Molecular Biology | Best Researcher Award

Dr. Kalim Ullah | Molecular Biology | Best Researcher Award

Ningbo university China | China

Author Profile

Scopus

🧬 Dr. Kalim Ullah – Molecular Biologist & Aquaculture Researcher 🐟🔬

Dr. Kalim Ullah is a dedicated researcher with a strong background in molecular biology, genetics, immunology, and aquaculture. His expertise lies in understanding the genetic and cellular mechanisms underlying aquatic species’ development, regeneration, and immune responses.

🎓 Education & Academic Excellence

  • Ph.D. in Aquaculture – Ningbo University, China
    Focus: Genetics, Molecular Biology & Immunology (CGPA: 3.75/4.00)
  • M.Phil. in Zoology – PMAS-Arid Agriculture University, Pakistan
    Focus: Aquaculture & Fisheries (CGPA: 3.68/4.00)
  • BS (Hons) in Zoology – University of Peshawar, Pakistan
    Focus: Aquaculture & Fisheries (CGPA: 3.6/4.0)
  • Higher Secondary & Secondary Education – Pakistan

🔬 Research Interests

✔ Molecular Biology
✔ Genetics
✔ Cell Biology & Immunology

🧪 Research Projects

📌 Ph.D.: Comparative transcriptome analysis & epigenetic profiling in silver pomfret caudal fin regeneration.
📌 M.Phil.: Effect of stocking density on growth performance of Indus Mahseer (Tor Maccrolepis).
📌 BS: Utilization of poultry farm waste as a protein and energy source in Labeo rohita diets.

💻 Technical Skills

🖥 Computer Skills: MS Office | Excel | SPSS | R (Data Analysis) | GraphPad Prism
🧬 Lab Skills: Cell Culture | qPCR & RT-PCR | Western Blotting | Genome Sequencing | Transcriptomics & Proteomics | Dual Luciferase Reporter Assay | TEM | In-Situ Hybridization
🗣 Languages: English | Urdu | Chinese (HSK-3)

Dr. Kalim Ullah continues to push the boundaries of genetics, aquaculture, and immunology, contributing valuable insights to the scientific community. 🚀🔬🐠

🏆 CONCLUSION

Dr. Kalim Ullah is a passionate and accomplished researcher at the intersection of molecular biology, genetics, immunology, and aquaculture. With a strong academic background, hands-on laboratory expertise, and a keen interest in advanced genetic and cellular studies, he is dedicated to driving scientific progress in aquatic species research, regenerative biology, and immune system studies. His contributions to transcriptomics, proteomics, and genome analysis highlight his ability to tackle complex biological challenges.

 

📊🔬NOTABLE PUBLICATION:
  1. Title: Improved efficacy of cisplatin delivery by peanut agglutinin‑modified liposomes in non‑small cell lung cancer
    Authors: B., Yang, Ben , R., Kou, Rongguan , H., Wang, Hui , … W., Yu, Wenjing , Z., Gao, Zhiqin
    Journal: International Journal of Molecular Medicine
    Year: 2024

 

  1. Title: Novel analgesic peptide derived from Cinobufacini injection suppressing inflammation and pain via ERK1/2/COX-2 pathway
    Authors: L., Guo, Li , S., Zhang, Sai , C., Zhang, Cong , … Y., Gao, Yuanyuan , T., Sun, Tongyi
    Journal: International Immunopharmacology
    Year: 2024

Yubing Wang | Oncology | Best Researcher Award

Assoc. Prof. Dr. Yubing Wang | Oncology | Best Researcher Award

Weifang No.2 People’s Hospital | China

AUTHOR PROFILE

Scopus

🔬 EARLY ACADEMIC PURSUITS

Yubing Wang embarked on his academic journey with a strong foundation in biosciences. In 2007, he earned his Bachelor’s degree in Bioscience from Shandong University, which laid the groundwork for his future endeavors in the field of biological and medical sciences. His passion for scientific research led him to pursue further studies, culminating in a Doctor of Science degree from The Chinese University of Hong Kong in 2017. This rigorous academic training provided him with expertise in advanced biological sciences and research methodologies, setting the stage for his future contributions to medical and bioscience research.

🏥 PROFESSIONAL ENDEAVORS

Dr. Wang’s professional career is marked by significant roles in both research and academia. His journey began as a Research Assistant at the Shanghai Institutes for Biological Sciences, CAS, where he worked for six years (2007–2013), gaining hands-on experience in cutting-edge biological research. Following this, he transitioned into academia, taking on the role of Associate Professor at Shandong Second Medical University from 2018 to 2023. His commitment to teaching and research was further recognized when he joined Weifang No.2 People’s Hospital as an Associate Professor in 2023, where he continues to contribute to the advancement of medical sciences.

📚 CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY

Dr. Wang’s research is centered around biosciences and medical applications, particularly in biological mechanisms and therapeutic developments. His work has contributed to a deeper understanding of biomedical sciences, with a focus on improving clinical outcomes through innovative research. His interdisciplinary approach combines molecular biology, biotechnology, and clinical applications, addressing critical medical challenges and advancing healthcare solutions.

🌍 IMPACT AND INFLUENCE

Throughout his career, Dr. Wang has played a pivotal role in bridging the gap between fundamental bioscience research and its practical applications in medicine. His work has influenced both the academic community and clinical practices, contributing to the development of novel medical treatments and diagnostic tools. By mentoring students and collaborating with fellow researchers, he has fostered a new generation of scientists committed to pushing the boundaries of medical research.

📖 ACADEMIC CITATIONS AND RECOGNITION

Dr. Wang’s research has been widely recognized in the academic community, with numerous scientific publications in reputed journals. His work has been cited by fellow researchers, reflecting the significance and impact of his contributions to biosciences and medical research. His research has also been instrumental in guiding clinical practices and informing new treatment methodologies.

🚀 LEGACY AND FUTURE CONTRIBUTIONS

As an esteemed academic and researcher, Dr. Wang continues to expand his influence in bioscience and medical research. His future endeavors aim to enhance interdisciplinary research collaborations, further the development of innovative healthcare solutions, and mentor the next generation of scientists and medical professionals. His work at Weifang No.2 People’s Hospital is expected to drive forward transformative research, ultimately improving patient care and advancing medical knowledge.

🏆 CONCLUSION

Dr. Yubing Wang’s career exemplifies a commitment to scientific excellence, academic mentorship, and transformative medical research. His contributions in biosciences and medicine have left a lasting impact on both academia and clinical practice. With his expertise and dedication, he continues to shape the future of biomedical research, paving the way for groundbreaking discoveries and improved healthcare outcomes. His legacy as a researcher and educator ensures that his influence will be felt for generations to come.

 

📊🔬NOTABLE PUBLICATION:
  1. Title: Improved efficacy of cisplatin delivery by peanut agglutinin‑modified liposomes in non‑small cell lung cancer
    Authors: B., Yang, Ben , R., Kou, Rongguan , H., Wang, Hui , … W., Yu, Wenjing , Z., Gao, Zhiqin
    Journal: International Journal of Molecular Medicine
    Year: 2024

 

  1. Title: Novel analgesic peptide derived from Cinobufacini injection suppressing inflammation and pain via ERK1/2/COX-2 pathway
    Authors: L., Guo, Li , S., Zhang, Sai , C., Zhang, Cong , … Y., Gao, Yuanyuan , T., Sun, Tongyi
    Journal: International Immunopharmacology
    Year: 2024

Di Fan | Molecular Imaging in Drug Development | Best Researcher Award

Ms. Di Fan | Molecular Imaging in Drug Development | Best Researcher Award

Capital Medical University | China

AUTHOR PROFILE

Scopus

📌 DI FAN, PhD

Associate Researcher
Department of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University

🎓 EDUCATION AND EARLY ACADEMIC PURSUITS

Di Fan pursued his Bachelor’s degree at Wuhan University (2006-2010), where he built a strong foundation in biomedical sciences. His passion for advanced medical research led him to Peking University (2010-2015), where he obtained his PhD. During his doctoral studies, he focused on radiopharmaceuticals and molecular imaging, setting the stage for a career dedicated to cutting-edge advancements in nuclear medicine.

🏥 PROFESSIONAL ENDEAVORS

Currently serving as an Associate Researcher at the Department of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Di Fan plays a pivotal role in advancing molecular imaging and targeted cancer therapies. His work bridges the gap between innovative radiopharmaceuticals and their clinical applications, contributing to the early detection and treatment of cancer.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS

Dr. Fan’s research is primarily focused on:

  • Radiopharmaceutical Development – Designing novel radioactive tracers for precise cancer imaging and treatment.
  • Molecular Imaging – Utilizing advanced PET and SPECT imaging techniques to enhance tumor detection and therapeutic monitoring.
  • Targeted Cancer Therapy – Developing radiolabeled compounds to selectively attack cancer cells, minimizing damage to healthy tissues.

His work contributes significantly to improving personalized cancer treatment, ensuring higher accuracy in diagnosis and therapy.

🌍 IMPACT AND INFLUENCE

Dr. Fan’s contributions have been recognized through numerous scientific publications, collaborations with leading medical institutions, and participation in national and international research projects. His expertise in nuclear medicine and molecular imaging has influenced both clinical practices and medical innovations in China and beyond.

📚 ACADEMIC CITES AND RECOGNITION

  • Published extensively in high-impact SCI-indexed journals related to radiopharmaceuticals and cancer imaging.
  • H-index and citations reflect his significant contribution to the field of nuclear medicine.
  • Regularly invited to present at global medical and radiology conferences, sharing insights on novel imaging techniques.

🚀 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Fan aims to:
✅ Develop next-generation radiopharmaceuticals for better cancer detection and treatment.
✅ Strengthen collaborations between academic and clinical institutions to enhance nuclear medicine applications.
✅ Advance precision oncology, integrating AI-driven analysis for personalized cancer therapies.

His research will continue shaping the future of molecular imaging and targeted therapies, ensuring breakthroughs in early cancer diagnosis and patient-centered treatments.

🧬CONCLUSION

Dr. Di Fan stands at the forefront of nuclear medicine research, making significant strides in radiopharmaceuticals, molecular imaging, and targeted cancer therapy. His dedication to scientific innovation and clinical application has not only enhanced cancer diagnostics and treatment but also paved the way for more effective and personalized medical approaches.

 

📊🔬NOTABLE PUBLICATION:
    1. Title: Utilisation of the Innovative [18F]-Labelled Radiotracer [18F]-BIBD-071 Within HR+ Breast Cancer Xenograft Mouse Models
      Authors: D., Fan, Di , X., Wang, Xin , X., Ling, Xueyuan , … Z., Wu, Zehui , L., Ai, Lin
      Journal: Pharmaceuticals
      Year: 2025

Jianqiang Wu | Melanoma | Best Researcher Award

Mr. Jianqiang Wu | Melanoma | Best Researcher Award

Guangzhou Medical University | China

AUTHOR PROFILE

ORCID ID

🏥MR. JIANQIANG WU: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Mr. Jianqiang Wu pursued his medical education with a focus on dermatology, establishing a strong foundation in medical sciences. His early academic years were marked by rigorous training, research involvement, and a keen interest in skin-related disorders, particularly melanoma.

🩺PROFESSIONAL ENDEAVORS

Currently serving at the Department of Dermatology, the Affiliated Panyu Central Hospital, Guangzhou Medical University, China, Mr. Wu has been an integral part of the institution’s dermatological research and clinical services. His dedication to patient care and medical research has significantly contributed to advancements in dermatology.

🔬CONTRIBUTIONS AND RESEARCH FOCUS

Mr. Wu has dedicated a substantial part of his career to the study and treatment of melanoma, a serious form of skin cancer. His research focuses on early diagnosis, innovative treatments, and improving therapeutic outcomes for melanoma patients. He has played a pivotal role in developing targeted therapies and exploring the genetic and molecular mechanisms underlying melanoma progression.

🌍IMPACT AND INFLUENCE

Through his research and clinical practice, Mr. Wu has influenced the field of dermatology, particularly in the early detection and treatment of melanoma. His work has led to improved diagnostic techniques and treatment protocols, benefiting patients in China and beyond. His contributions to medical education have also guided the next generation of dermatologists.

📚ACADEMIC CITATIONS

Mr. Wu’s research findings have been widely cited in peer-reviewed journals, reflecting their significance in the scientific community. His publications contribute to a growing body of knowledge in dermatology, particularly in melanoma treatment strategies.

🏆LEGACY AND FUTURE CONTRIBUTIONS

With a strong track record in clinical and academic dermatology, Mr. Wu’s legacy is marked by his commitment to advancing melanoma research. His future endeavors may include further innovation in personalized medicine, novel therapeutic approaches, and international collaborations to combat skin cancer more effectively.

💊OTHER IMPORTANT TOPICS

  • Collaborations: Engages in interdisciplinary collaborations with oncologists, geneticists, and immunologists to enhance melanoma treatment.
  • Mentorship: Actively mentors young dermatologists, contributing to the academic and professional growth of upcoming medical professionals.
  • Public Health Initiatives: Involved in skin cancer awareness campaigns, promoting early detection and prevention measures in the community.
  • Technological Integration: Advocates for the use of AI and advanced imaging technologies in dermatological diagnostics.

🧬CONCLUSION

Mr. Jianqiang Wu has made remarkable contributions to the field of dermatology, particularly in melanoma research and treatment. His dedication to patient care, innovative research, and academic mentorship ensures that his impact will be felt for years to come. As he continues to push the boundaries of dermatological science, his work stands as a testament to his unwavering commitment to medical advancement and improved patient outcomes.

 

📊🔬NOTABLE PUBLICATION:
    1. Title: CRIP1 inhibits cutaneous melanoma progression through TFAM-mediated mitochondrial biogenesis
      Authors: Jianqiang Wu, Lixia Chen, Peijun Wen.
      Journal: Scientific Reports
      Year: 2025

Guohua Yang | Medical Genetics | Best Researcher Award

Assoc. Prof. Dr. Guohua Yang | Medical Genetics | Best Researcher Award

Wuhan University | China

Author Profile

ORCID ID

🔬🧬 Prof. Guohua Yang – Associate Professor, Wuhan University

Expert in Medical Genetics & Precision Medicine

🏛️ Institution: Wuhan University
🎓 Academic Focus: Medical Genetics, Gene Mutation & Disease Mechanisms

🔍 Research Interests:

  • 🧬 Gene Mutations & Genetic Diseases – Understanding the functional impact of genetic variations.
  • 🏥 Innovative Gene Diagnosis – Developing cutting-edge diagnostic methods for hereditary conditions.
  • 🦠 Hepatocellular Carcinoma – Investigating molecular mechanisms and drug discovery strategies.

📌 Leadership & Professional Roles:

  • 👨‍⚕️ Chairman, Gene Health Branch, Hubei Genetic Society
  • 🏥 Standing Committee Member, Reproductive Genetics Branch, Hubei Reproductive Health Society
  • 🧑‍⚕️ Member, Medical Genetics Branch, Hubei Medical Association
  • 👶 Committee Member, Fertility Protection & Restoration, China Association for Healthy Children
  • 🏥 Deputy Director, Precision Medicine Committee, Zhongguancun Cancer Minimally Invasive Treatment Alliance

📚 Editorial Appointments:

  • ✍️ Guest Editor, Frontiers in Genetics (Monogenic Diseases Column)
  • 📖 Editorial Board Member, Spandidos Journal, Brain Research

🏆CONCLUSION 

Prof. Guohua Yang is a leading expert in medical genetics and precision medicine, making significant contributions to gene mutation research, innovative genetic diagnostics, and hepatocellular carcinoma treatment. As a key figure in multiple academic and professional organizations, his leadership and editorial roles further strengthen his impact in the field. His dedication to advancing genetic research and clinical applications continues to shape the future of genomic medicine and personalized healthcare. 🏥🧬

 

📊🔬NOTABLE PUBLICATION:
  • Title: Clinic Examination and Gene Diagnosis for a Birt–Hogg–Dubé Syndrome Family With a Novel FLCN Frameshift Mutation Causing Nonsense‐Mediated mRNA Degradation.
    Authors: 
    Yang Xu, Jie Gao, Yang An, Chenxi Zou, Guoqing Ding, Guohua Yang, Finlay Macrae.
    Journal: Human Mutation
    Year: 2025

 

  • Title: A Novel TSC1 Frameshift Mutation c.1550_1551del Causes Tuberous Sclerosis Complex by Aberrant Splicing and Nonsense‐Mediated mRNA Degradation (NMD) Simultaneously in a Chinese Family.
    Authors:
     Cong Qiu, Chengyan Li, Xiaoyun Tong, Luoyang Dai, Wenda Liu, Yulie Xie, Qimei Zhang, Guohua Yang, Tao Li.
    Journal: Molecular Genetics & Genomic Medicine
    Year: 2020

 

  • Title: Identification and Interaction Analysis of Significant Genes and MicroRNAs in Pterygium.
    Authors:
     Siying He, Hui Sun, Yifang Huang, Shiqi Dong, Chen Qiao, Shuai Zhang, Chen Wang, Fang Zheng, Ming Yan, Guohua Yang.
    Journal: BioMed Research International
    Year: 2019

Yong Qian | Nanomedicine | Best Researcher Award

Dr. Yong Qian | Nanomedicine | Best Researcher Award

Hefei Institute of Physical Science, Chinese Academy of Sciences | China

AUTHOR PROFILE

Scopus

YONG QIAN 📚

🎓EARLY ACADEMIC PURSUITS 

Yong Qian embarked on his academic journey at Anhui University of Technology, where he earned a Bachelor’s degree in Materials Science and Engineering (2014-2018). He further honed his expertise by pursuing a Master’s degree at the University of Anhui (2018-2021), delving deeper into materials science. His passion and commitment led him to achieve a Doctorate in Materials Science and Engineering from the prestigious University of Science and Technology of China (2021-2024).

🏢PROFESSIONAL ENDEAVORS 

Currently serving as a Postdoctoral Researcher at the Hefei Institute of Physical Science, Chinese Academy of Sciences since June 2024, Yong Qian is engaged in pioneering research within the field of materials science. His role involves conducting advanced experimental studies, collaborating with interdisciplinary teams, and contributing to groundbreaking projects aimed at innovating material applications.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON NANOMEDICINE

Yong Qian’s research focuses on the development and application of novel materials, particularly exploring their potential in energy storage and conversion systems. His work is characterized by a deep understanding of material properties and innovative approaches to solving real-world challenges. He has actively contributed to the enhancement of materials with improved efficiency and sustainability.

🌟IMPACT AND INFLUENCE 

Through his rigorous research efforts, Yong Qian has influenced both academic and industrial communities. His findings have been published in several high-impact journals, contributing valuable knowledge to the field of materials science. He has also participated in international conferences, presenting his work to a global audience and fostering collaborations.

📈ACADEMIC CITES AND RECOGNITION 

Yong Qian’s research outputs have garnered significant attention, resulting in numerous citations that highlight the relevance and impact of his work. His contributions have been acknowledged by peers and senior researchers, establishing him as a promising figure in materials science.

🌍LEGACY AND FUTURE CONTRIBUTIONS 

Looking ahead, Yong Qian aims to expand his research into sustainable materials for environmental applications, with a particular focus on renewable energy technologies. His vision is to lead projects that bridge the gap between fundamental research and practical applications, ensuring that scientific advancements contribute to global sustainability goals.

🏆CONCLUSION 

Yong Qian’s journey from academic excellence to professional innovation underscores his dedication to materials science. His contributions to research and sustainability efforts reflect his commitment to making a meaningful impact. With a strong foundation and a forward-thinking vision, he is poised to drive significant advancements in his field, inspiring future generations of researchers.

 

📊🔬NOTABLE PUBLICATION:
    1. Title: Hollow Cuprous Oxide@Nitrogen-Doped Carbon Nanocapsules for Cascade Chemodynamic Therapy
      Authors: Meng, X.; Zhou, K.; Qian, Y.; … Qian, J.; Wang, H.
      Journal: Small
      Year: 2022

 

    1. Title: NIR-II Responsive PEGylated Nickel Nanoclusters for Photothermal Enhanced Chemodynamic Synergistic Oncotherapy
      Authors: Qian, Y.; Zhang, J.; Zou, J.; … Lin, W.; Wang, H.
      Journal: Theranostics
      Year: 2022

 

    1. Title: Ultrasmall Cu Nanocrystals Dispersed in Nitrogen-Doped Carbon as Highly Efficient Catalysts for CO₂ Electroreduction
      Authors: Meng, X.; Pan, G.; Liu, H.; … Wang, H.; Chen, Q.
      Journal: ACS Applied Materials and Interfaces
      Year: 2022

 

    1. Title: Carbon-Encapsulated Magnetite Nanodoughnut as a NIR-II Responsive Nanozyme for Synergistic Chemodynamic–Photothermal Therapy
      Authors: Meng, X.; Zhang, Z.; Qian, Y.; … Zhang, M.; Wang, H.
      Journal: Advanced Healthcare Materials
      Year: 2023

 

    1. Title: Magnetic Field-Induced Synthesis of One-Dimensional Nickel Nanowires for Enhanced Microwave Absorption
      Authors: Qian, Y.; Meng, X.; Liu, H.; … Sheng, Z.; Wang, H.
      Journal: Advanced Materials Interfaces
      Year: 2023

Prof. Kui Liu | Breast Cancer | Best Researcher Award

Prof. Kui Liu | Breast Cancer | Best Researcher Award

Zibo Central Hospital | China

AUTHOR PROFILE

Scopus

KUI LIU, Ph.D. – PROFESSIONAL PROFILE

🎓 EARLY ACADEMIC PURSUITS

Kui Liu embarked on a robust academic journey in clinical and diagnostic sciences:

  • 2002-2005: Completed a degree in Clinical Laboratory Medicine from Linyi Medical College, China.
  • 2012-2015: Pursued a master’s degree in Clinical Laboratory Diagnostics at Jiangsu University, Zhenjiang, China.
  • 2016-2020: Earned a Ph.D. in Immunology from Southeast University, Nanjing, China, contributing significantly to the field with innovative research in immune responses and diagnostics.

💼 PROFESSIONAL ENDEAVORS

Kui Liu has accumulated extensive clinical and technical experience over nearly two decades:

  • 2020-Present: Associate Chief Technician at the Center of Translational Medicine, Zibo Central Hospital, where he plays a key role in integrating research with clinical applications.
  • 2015-2016: Worked as a Docimaster at the Blood Bank of the First Hospital of Zibo, focusing on blood storage and safety protocols.
  • 2008-2012: Served as a Docimaster at the same institution, ensuring high-quality diagnostic practices.
  • 2005-2008: Began his career as a Docimaster in the Laboratory Department, excelling in clinical diagnostics.

🧪 CONTRIBUTIONS AND RESEARCH FOCUS ON BREAST CANCER

Kui Liu’s research is centered on advancing the fields of immunology and clinical diagnostics, with a focus on:

  • The study of immune responses in various pathological conditions.
  • Development of innovative diagnostic tools and techniques.
  • Translation of scientific research into clinical solutions.

His work on immune mechanisms and diagnostic technologies has led to groundbreaking advancements in translational medicine.

💡 FUNDING AND RESEARCH IMPACT

Kui Liu has been a driving force behind several high-impact research projects, securing prestigious grants to fund cutting-edge studies:

  • Grant no. 81602330: Principal Investigator for the National Natural Science Foundation of China (2017-2019), focusing on immunological research.
  • Grant no. 81972002: Co-Investigator for the National Natural Science Foundation of China (2019-2022), contributing to collaborative advancements in the field.
  • Grant no. J18KA299: Co-Investigator in the Shandong Province Higher Educational Science and Technology Program (2019-2021).
  • Grant no. ZR2015PH056: Co-Investigator for the Natural Science Foundation of Shandong Province (2015-2016).
  • Grant no. CXLX13_689: Principal Investigator for the Innovation Project of Cultivating Graduates of Jiangsu Province (2013-2015).

🌍 IMPACT AND INFLUENCE

  • Innovator in Translational Medicine: Kui Liu has bridged the gap between laboratory research and clinical application, enhancing diagnostic capabilities in immunology.
  • National and Regional Contributions: Through leadership in provincial and national projects, he has elevated the standards of diagnostic medicine across China.
  • Collaboration and Mentorship: Actively fosters collaborations and guides aspiring researchers, contributing to the growth of the next generation of medical scientists.

📚 ACADEMIC CITES AND RECOGNITION

Kui Liu has received widespread recognition for his contributions, reflected in numerous citations and acknowledgments in scientific journals. His findings have influenced medical practices and inspired continued exploration in immunology.

🌟 LEGACY AND FUTURE CONTRIBUTIONS

Kui Liu’s career is a testament to his commitment to advancing medical science. His future endeavors include:

  • Leading innovative studies in immunological diagnostics.
  • Expanding the applications of translational medicine.
  • Continuing to inspire young researchers through mentorship and collaboration.

🌟CONCLUSION 

Dr. Kui Liu’s remarkable journey from foundational clinical studies to advanced immunological research exemplifies a career dedicated to innovation, excellence, and impact. His contributions to translational medicine and diagnostics have not only advanced scientific understanding but also improved clinical practices, particularly in immunology.

 

📊🔬NOTABLE PUBLICATION:
    1. Title: LncRNA DANCR-miR-758-3p-PAX6 Molecular Network Regulates Apoptosis and Autophagy of Breast Cancer Cells
      • Authors: Zhang, X.H., Li, B.F., Ding, J., Ma, F.X., Wu, X.Y.
      • Journal: Cancer Management and Research
      • Year: 2020

    1. Title: LncRNA PVT1 Regulates Gallbladder Cancer Progression through miR-30d-5p
      • Authors: Liu, K., Xu, Q.
      • Journal: Journal of Biological Regulators and Homeostatic Agents
      • Year: 2020

    1. Title: TIPE1 Inhibits Osteosarcoma Tumorigenesis and Progression by Regulating PRMT1 Mediated STAT3 Arginine Methylation
      • Authors: Yang, M., Zhang, Y., Liu, G., Liu, Q., Zhao, P.
      • Journal: Cell Death and Disease
      • Year: 2022

    1. Title: CircRNA hsa_circ_0008500 Acts as a miR-1301-3p Sponge to Promote Osteoblast Mineralization by Upregulating PADI4
      • Authors: Zhai, Q., Zhao, Y., Wang, L., Li, T., Wang, L.
      • Journal: Frontiers in Cell and Developmental Biology
      • Year: 2020

    1. Title: miR-369-3p Inhibits Tumorigenesis of Hepatocellular Carcinoma by Binding to PAX6
      • Authors: Xu, Q., Liu, K.
      • Journal: Journal of Biological Regulators and Homeostatic Agents
      • Year: 2020

Assoc. Prof. Dr. Feng Li | Tumor | Best Researcher Award

Assoc. Prof. Dr. Feng Li | Tumor | Best Researcher Award

Qufu Normal University | China

AUTHOR PROFILE

Scopus

Google Scholar

🏫 EARLY ACADEMIC PURSUITS

Assoc. Prof. Dr. Feng Li began their academic journey with a solid foundation in the life sciences, focusing on biology and computational biology during their undergraduate and graduate studies. They earned advanced degrees specializing in bioinformatics and oncology-related research, which positioned them at the intersection of biological data analysis and tumor research. Their early years were marked by exceptional performance, earning scholarships and accolades for academic excellence.

💼 PROFESSIONAL ENDEAVORS

Dr. Feng Li currently serves as an Associate Professor at Qufu Normal University in China. They have built a career that bridges teaching, research, and mentorship, shaping the next generation of scientists in the field of tumor biology and bioinformatics. They also collaborate with leading researchers and institutions, contributing to multidisciplinary projects and promoting innovation in their field.

🧬 CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR

Dr. Li’s primary research focus lies in tumor biology, particularly the application of bioinformatics to understand cancer mechanisms. Their work emphasizes:

  • Identifying biomarkers for cancer diagnostics and therapy.
  • Analyzing genomic and proteomic data to uncover tumor-related pathways.
  • Developing predictive models for patient outcomes using machine learning.

Their groundbreaking research has led to the publication of numerous peer-reviewed articles, advancing knowledge in cancer genomics and computational oncology.

🌍 IMPACT AND INFLUENCE

Through their research, Dr. Feng Li has significantly impacted the scientific community by:

  • Enhancing the understanding of cancer biology.
  • Introducing innovative bioinformatics tools for data analysis.
  • Influencing clinical practices with actionable insights from their studies.

Their work is frequently cited, reflecting their contributions to the broader academic discourse in oncology and bioinformatics.

📊 ACADEMIC CITES

Dr. Li’s publications have garnered widespread recognition, with a growing H-index reflecting their influence in the academic community. Their articles are cited by researchers worldwide, signifying the value and relevance of their findings.

🏅 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Feng Li’s legacy is marked by their dedication to advancing cancer research and mentoring young scientists. Looking ahead, their focus includes:

  • Expanding research in personalized cancer therapies.
  • Fostering collaborations between bioinformatics and clinical oncology.
  • Inspiring future generations through teaching and research initiatives.

🌟 OTHER IMPORTANT TOPICS

  • Teaching Excellence: Dr. Li is recognized for their engaging teaching methods, integrating real-world research into classroom learning.
  • Community Engagement: Actively participates in academic conferences and workshops, sharing their expertise and fostering knowledge exchange.
  • Interdisciplinary Approach: Their work exemplifies how bioinformatics and oncology can converge to solve complex medical challenges.

🌟CONCLUSION 

Assoc. Prof. Dr. Feng Li has emerged as a pivotal figure in the fields of tumor biology and bioinformatics, blending academic rigor with innovative research to tackle some of the most pressing challenges in oncology. Through their groundbreaking contributions, impactful teaching, and dedication to interdisciplinary collaboration, Dr. Li has left an indelible mark on the scientific community.

 

📊🔬NOTABLE PUBLICATION:
  • 1. SLGCN: Structure-enhanced line graph convolutional network for predicting drug–disease associations
    • Authors: Liu, B.-M., Gao, Y.-L., Li, F., Zheng, C.-H., Liu, J.-X.
    • Journal: Knowledge-Based Systems
    • Year: 2024

    2. A framework for scRNA-seq data clustering based on multi-view feature integration

    • Authors: Li, F., Liu, Y., Liu, J., Ge, D., Shang, J.
    • Journal: Biomedical Signal Processing and Control
    • Year: 2024

    3. KFDAE: CircRNA-Disease Associations Prediction Based on Kernel Fusion and Deep Auto-Encoder

    • Authors: Kang, W.-Y., Gao, Y.-L., Wang, Y., Li, F., Liu, J.-X.
    • Journal: IEEE Journal of Biomedical and Health Informatics
    • Year: 2024

    4. Multi-Affinity network integration based on multi-omics data for tumor stratification

    • Authors: Li, F., Gao, Y., Sun, Z., Shang, J., Liu, J.-X.
    • Journal: Biomedical Signal Processing and Control
    • Year: 2025

    5. A review: simulation tools for genome-wide interaction studies

    • Authors: Shang, J., Xu, A., Bi, M., Li, F., Liu, J.-X.
    • Journal: Briefings in Functional Genomics
    • Year: 2024

Prof. Hao Peng | RNA Epigenetic | Best Researcher Award

Prof. Hao Peng | RNA Epigenetic | Best Researcher Award

Guangdong Provincial People’s Hospital | China

AUTHOR PROFILE

Scopus

👩‍⚕️PROFESSOR YINGFEN YING: A DISTINGUISHED MEDICAL PROFESSIONAL🌍

📘 EARLY ACADEMIC PURSUITS

Prof. Hao Peng’s academic journey began with graduate studies at Sun Yat-sen University Cancer Center, where he laid the groundwork for his expertise in oncology. Following this, he undertook postdoctoral research at the First Affiliated Hospital of Sun Yat-sen University. This period marked his immersion in groundbreaking research, fostering a deep interest in RNA epigenetic modifications and their role in cancer biology.

💼 PROFESSIONAL ENDEAVORS

Currently a Professor and Surgical Oncologist at Guangdong Provincial People’s Hospital in China, Prof. Peng combines clinical practice with impactful research. His dual roles allow him to contribute both to patient care and the academic community, exemplifying the integration of clinical insights into scientific discovery.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON RNA EPIGENETIC

Prof. Peng’s primary research interests revolve around RNA epigenetic modifications in cancer, particularly:

  • tRNA m7G modification
  • 18S rRNA m6A modification
  • 28S rRNA m6A modification

He has elucidated how these modifications regulate mRNA translation and promote cancer progression. His findings have significantly enhanced the understanding of molecular mechanisms underlying oncogenesis.

🌍 IMPACT AND INFLUENCE

Prof. Peng has established himself as a thought leader in oncology, publishing several high-impact papers as the first and corresponding author in prestigious journals, including:

  • Nature Metabolism
  • Cell Reports
  • Cell Chemical Biology
  • Oncogene

These publications have contributed to advancing RNA epigenetics and its implications in cancer biology.

📊 ACADEMIC CITATIONS

With a growing citation impact, Prof. Peng’s research is widely referenced in the field, highlighting his influence on oncology research. His innovative work in RNA modifications has positioned him as a respected voice in his domain, shaping future studies in cancer therapeutics.

🔑 LEGACY AND FUTURE CONTRIBUTIONS

Prof. Peng has hosted multiple national research funds, emphasizing his role in advancing cancer research in China. His dedication to mentorship and collaboration ensures a lasting legacy in oncology. His ongoing research in RNA modifications holds promise for the development of novel therapeutic strategies, bridging the gap between molecular discoveries and clinical applications.

🏆 RECOGNITIONS AND LEADERSHIP

As a leader in the field, Prof. Peng continues to drive innovation in oncology. His contributions have earned him national recognition, solidifying his reputation as a pioneer in RNA epigenetics and its translational potential in cancer treatment.

🌟CONCLUSION 

Prof. Hao Peng’s exemplary career demonstrates the transformative impact of integrating molecular research with clinical practice. His pioneering work in RNA epigenetic modifications has reshaped the understanding of cancer progression and mRNA translation regulation. With a robust portfolio of influential publications, funded research projects, and a commitment to advancing oncology, Prof. Peng is not only contributing to the present scientific landscape but also paving the way for future breakthroughs in cancer therapeutics. His dedication to innovation, mentorship, and collaboration ensures a lasting legacy in the fight against cancer, inspiring both his peers and the next generation of researchers.

 

📊🔬NOTABLE PUBLICATION:
  • N7-methylguanosine tRNA modification promotes esophageal squamous cell carcinoma tumorigenesis via the RPTOR/ULK1/autophagy axis
    • Authors: Han, H.; Yang, C.; Ma, J.; …; Choe, J.; Lin, S.
    • Journal: Nature Communications
    • Year: 2022

 

  • N6-methyladenosine (m6A) in 18S rRNA promotes fatty acid metabolism and oncogenic transformation
    • Authors: Peng, H.; Chen, B.; Wei, W.; …; Kuang, M.; Lin, S.
    • Journal: Nature Metabolism
    • Year: 2022

 

  • N7-methylguanosine tRNA modification promotes tumorigenesis and chemoresistance through WNT/β-catenin pathway in nasopharyngeal carcinoma
    • Authors: Chen, B.; Jiang, W.; Huang, Y.; …; Wu, L.; Peng, H.
    • Journal: Oncogene
    • Year: 2022

 

  • N6-methyladenosine modification in 18S rRNA promotes tumorigenesis and chemoresistance via HSF4b/HSP90B1/mutant p53 axis
    • Authors: Chen, B.; Huang, Y.; He, S.; …; Wu, L.; Peng, H.
    • Journal: Cell Chemical Biology
    • Year: 2023

 

  • Nomogram-aided individual induction chemotherapy regimen selection in advanced nasopharyngeal carcinoma
    • Authors: Peng, H.; Chen, L.; Mao, Y.-P.; Tian, L.; Liu, L.-Z.
    • Journal: Oral Oncology
    • Year: 2021